ArticleOpen access rheumatology : research and reviews2026
Exploring the Toxicological Effects of Acetyl Tributyl Citrate Exposure on Osteoarthritis Based on Machine Learning, Network Toxicology and Molecular Docking Analysis.
Article in Open access rheumatology : research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the potential toxicological effects of acetyl tributyl citrate (ATBC) on osteoarthritis (OA) and elucidate the underlying mechanisms using bioinformatics, machine learning, and network toxicology. Methods: ATBC targets were identified from multiple databases, and OA-associated differentially expressed genes (DEGs) were sourced from GSE51588. Intersection analysis identified common targets. Functional enrichment and protein-protein interaction (PPI) network analysis were performed. Machine learning algorithms (LASSO, Random Forest and SVM) validated core targets, with ROC curves assessing diagnostic potential. Immune infiltration differences were analyzed via Cibersort. Molecular docking confirmed ATBC binding to core targets, and an adverse outcome pathway (AOP) framework was developed to elucidate ATBC's role in exacerbating OA through key genes and pathways. Results: Intersection analysis identified 40 common targets related to both ATBC and OA. Functional enrichment analysis revealed that these targets were significantly involved in calcium signaling pathways and neuroactive ligand-receptor interactions, both of which are implicated in OA pathogenesis. The PPI network analysis identified TNF, MMP8, CXCR4, and SLC2A1 as core targets. Machine learning algorithms further validated these core targets. ROC curve analysis showed that these genes have diagnostic potential, with AUC values ranging from 0.762 to 0.970. Immune infiltration analysis using Cibersort revealed significant differences in immune cell infiltration between OA and control groups, with core targets showing distinct correlations with various immune cells. Molecular docking confirmed strong binding affinities between ATBC and the core targets, with binding energies less than -5 kcal/mol. A novel adverse outcome pathway (AOP) framework was established, suggesting that ATBC may influence the expression of TNF, CXCR4, MMP8, and SLC2A1, with the calcium signaling and neuroactive ligand-receptor interaction pathways potentially contributing to immune dysregulation and OA progression. Conclusion: The identification of key targets (TNF, MMP8, CXCR4, and SLC2A1) and molecular docking results elucidates potential mechanisms by which ATBC exposure may exacerbate OA progression. The AOP provides evidence for joint-health risk assessment of plasticizers and offers readily measurable biomarkers for regulatory toxicology and future therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.